FIG 3.

Administration of CRO eradicated vaginal infection in SC6-infected mice, but not in those infected with SC7. Mice infected vaginally with SC7 (circles) or SC6 (triangles) were treated on day 0 (arrow) with CRO using either a 60-mg/kg TID (red) or a 120-mg/kg BID (blue) dosing regimen (n = 17 or 18 mice/group). PBS TID (black) was administered as a negative control. (A) All mice infected with SC6 that received CRO in a 60-mg/kg TID dosing regimen cleared infection within 72 h posttreatment, and there was a significantly greater clearance rate in SC7-infected mice that received the 60-mg/kg TID regimen (P = 0.0006). (B) There was a significant reduction in the average number of CFU/ml recovered from CRO-treated mice infected with either SC7 or SC6 compared to the average number recovered from mice in the PBS vehicle control group (P < 0.01). There was a significant reduction in the average bacterial burden in SC6-infected mice that received CRO compared to the results for CRO treatment of SC7 mice on days 7 and 8 posttreatment (*, P < 0.0001). (C) All SC6-infected mice that received 120 mg/kg CRO BID cleared infection within 72 h posttreatment, while in comparison, SC7-infected mice receiving this regimen remained 30% colonized through day 8 posttreatment. Groups infected with either strain that received CRO had a significant reduction in the number of infected mice compared to groups that received the corresponding PBS negative control (P < 0.02). (D) There was a significant reduction in the average number of CFU/ml recovered from CRO-treated mice infected with either SC7 or SC6 when compared to the results for the PBS vehicle control group for each infection (P < 0.0008).